From 2006 to 2008, several studies showed the importance of the KRAS oncogene in the treatment of metastatic colorectal cancer (mCRC) and response to anti-EGFR therapies as cetuximab or panitumumab [2–6]. Here, KRAS is linked to metastatic colorectal cancer.